FDA Accepts Allergan's sBLA for OnabotulinumtoxinA in Masseter Prominence
The FDA has accepted Allergan Aesthetics' sBLA for onabotulinumtoxinA to improve masseter muscle prominence, moving Botox toward a first-of-its-kind US label for jawline contouring.